A Pharmacokinetic Study of Omaveloxolone in Healthy Volunteers

Inclusion Criteria: * Male or female and age is between 18 and 55 years, inclusive; * All female subjects must have negative results for pregnancy tests performed; * If male, subject must be surgically sterile or practicing at least 1 of the following methods of contraception, from initial study drug administration through 90 days after administration of the last dose of study drug; * If male, subject agrees to abstain from sperm donation through 90 days after administration of the last dose of study drug; * Body Mass Index (BMI) is ≥ 18 to ≤ 31 kg/m2, inclusive; * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG), as judged by the investigator. Exclusion Criteria: * Presence or history of any significant cardiovascular, gastrointestinal, hepatic, renal, pulmonary, hematologic, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease, as determined by the investigator; * Presence of any other condition (including surgery) known to interfere with the absorption, distribution, metabolism, or excretion of medicines; * Requirement for any over-the-counter and/or prescription medication, vitamins, and/or herbal supplements on a regular basis; * Recent (6-month) history of drug or alcohol abuse; * Receipt of any investigational product within a time period equal to 10 half-lives of the product, if known, or a minimum of 30 days prior to study drug administration; * Positive screen results for drugs of abuse, alcohol, or cotinine at screening or Day -1; * Consumption of alcohol within 72 hours prior to study drug administration; * Consumption of grapefruit, grapefruit products, star fruit, star fruit products, or Seville oranges within the 72-hour period prior to study drug administration; * Use of tobacco or nicotine-containing products within the 6-month period preceding study drug administration; * 17.10. Current enrollment in another clinical study.